financetom
Business
financetom
/
Business
/
Form 8.3 - Dowlais Group PLC
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Form 8.3 - Dowlais Group PLC
Oct 9, 2025 3:05 AM

LONDON--(BUSINESS WIRE)--

 

FORM 8.3

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser:

Qube Research & Technologies Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Dowlais Group PLC ( DWLAF )

If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

 

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

08-10-2025

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

American Axle & Manufacturing Holdings Inc

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

44,961,051

3.41

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

TOTAL:

44,961,051

3.41

0

0.00

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:

0

Details, including nature of the rights concerned and relevant percentages:

0

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit (GBp)

(b) Cash-settled derivative transactions

Class of relevant security

Product description

e.g. call option

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of securities

Exercise price per unit (GBp)

1p ordinary

equity swap

decreasing a long position

1728

78.65

1p ordinary

equity swap

decreasing a long position

2218

78.70

1p ordinary

equity swap

decreasing a long position

1825

78.80

1p ordinary

equity swap

decreasing a long position

3435

78.95

1p ordinary

equity swap

decreasing a long position

46640

79.00

1p ordinary

equity swap

decreasing a long position

1584

79.05

1p ordinary

equity swap

decreasing a long position

8872

79.25

1p ordinary

equity swap

decreasing a long position

7935

79.30

1p ordinary

equity swap

decreasing a long position

8061

79.35

1p ordinary

equity swap

decreasing a long position

7098

79.40

1p ordinary

equity swap

decreasing a long position

19174

79.45

1p ordinary

equity swap

decreasing a long position

13332

79.50

1p ordinary

equity swap

decreasing a long position

20571

79.55

1p ordinary

equity swap

decreasing a long position

2796

79.60

1p ordinary

equity swap

decreasing a long position

9853

79.65

1p ordinary

equity swap

decreasing a long position

4866

79.70

1p ordinary

equity swap

decreasing a long position

3615

79.75

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit (GBp)

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit
(GBp)

(ii) Exercise

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

0

0

0

0

 

0

(d) Other dealings (including subscribing for new securities)

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

0

 

0

0

0

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

 

None

 

(c) Attachments

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

44,961,051

3.41

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

TOTAL:

44,961,051

3.41

0

0.00

0

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

0

0.00

0

0.00

(2) Cash-settled derivatives:

44,961,051

3.41

0

0.00

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

0

0.00

0

0.00

TOTAL:

44,961,051

3.41

0

0.00

1

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s disclosure requirements on +44 (0)20 7638 0129. The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

Source: Qube Research & Technologies LTD

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
China's Ant Group appoints new president in biggest reshuffle since regulatory revamp
China's Ant Group appoints new president in biggest reshuffle since regulatory revamp
Mar 19, 2024
SHANGHAI (Reuters) -Han Xinyi will become president of China's Ant Group and some units of the financial technology company will set up their own boards of directors to operate more independently, according to a source who saw an internal email from Ant CEO and chairman Eric Jing on Tuesday. Ant Group did not immediately respond to a request for comment....
International Flavors and Fragrances to sell pharma unit in $2.85 bln deal
International Flavors and Fragrances to sell pharma unit in $2.85 bln deal
Mar 19, 2024
March 19 (Reuters) - Chemicals company International Flavors & Fragrances ( IFF ) said on Tuesday it would sell its pharma solutions business to Roquette in a deal valued at $2.85 billion, as it looks to focus on higher-margin businesses. ...
--International Flavors & Fragrances to Sell Pharma Solutions Unit to Roquette for Up to $2.85 Billion
--International Flavors & Fragrances to Sell Pharma Solutions Unit to Roquette for Up to $2.85 Billion
Mar 19, 2024
06:57 AM EDT, 03/19/2024 (MT Newswires) -- Price: 84.65, Change: +0.84, Percent Change: +1 ...
Centers for Medicare & Medicaid Services Awards Contract to CGI to Improve Medicare Access for Over 65 Million Beneficiaries
Centers for Medicare & Medicaid Services Awards Contract to CGI to Improve Medicare Access for Over 65 Million Beneficiaries
Mar 19, 2024
06:58 AM EDT, 03/19/2024 (MT Newswires) -- The Centers for Medicare & Medicaid Services has awarded a contract to CGI Federal Inc., a wholly-owned US operating subsidiary of CGI Inc. , to improve Medicare access for more than 65 million beneficiaries nationwide, the company said Tuesday. CGI Federal will augment the agency's Health Plan Management System to optimize the plan...
Copyright 2023-2026 - www.financetom.com All Rights Reserved